Nasdaq December 6, 2022
Mental health issues are a growing concern in the United States. According to the National Institute of Mental Health (NIMH), nearly 20% of adults, or 43 million people, suffer from some form of mental illness annually. Conditions can range from mild states like depression and anxiety to more severe conditions like dementia, bipolar disorder, and schizophrenia. Below we will cover three pioneering biotech stocks with unique product offerings looking to address mental illness needs:
ATAI Life Sciences
When you think of drugs such as Ketamine or Psilocybin, you probably think of hippies and Woodstock, not medical treatments. ATAI Life Sciences ATAI is trying to flip that narrative. The German-based company, which IPOed in mid-2021, was founded by Florian Brand, a...
Today's Sponsors
Today's Sponsor